Scrip is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Innate Pharma's Expanded IO AstraZeneca Deal Jump-Starts US Ambitions

Executive Summary

France's Innate Pharma gets a boost to its plans to become a fully integrated biotech by forging a long-term immuno-oncology development partnership with AstraZeneca, and the setting up of a commercialization team in the US.

You may also be interested in...



AstraZeneca Pulls Plug On Lumoxiti Due To Low Uptake

Signs of trouble were already emerging in 2020 when Innate backed out of a co-commercialization pact. AstraZeneca plans to discontinue the hairy cell leukemia ADC in July.

Innate Lead Candidate Fails In Head And Neck Cancer But Partner AZ Offers Hope In NSCLC

Innate’s lead candidate has reached the end of the road in head and neck carcinoma after a disappointing interim Phase III trial analysis but hope remains that a combination with partner AstraZeneca's Imfinzi could succeed elsewhere.

Chastened Innate Returns Lumoxiti Rights To AZ

The French firm gave back the rights to Lumoxiti on the same day the drug got a thumbs up from the CHMP after struggling to market the rare leukemia drug in the US.

Related Content

Topics

Related Companies

Latest Headlines
See All
UsernamePublicRestriction

Register

SC124044

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Thank you for submitting your question. We will respond to you within 2 business days. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel